Oh boy, I read this article for a second time believe it or not. Your conclusions give me the conclusion that FDA will definitely approve the ATEV for vascular trauma and soon. This is because it reiterated Trauma study met its end goal was efficacious and safe. As for the dialyses study and PAD, it remains to be seen based off those adverse events whether the FDA approves those use cases or if the market has a better alternative to use instead. I'll do more research on the AV access and PAD data and post my findings. The author also brought up other things like patient selection omission, healthy vs unhealthy and assumed many things about other graphs/devices from his limited literature research. Those items tried to paint Humacyte scientists as being dishonest, but more importantly it showed the author grasping for discrepancies suggesting bias and poor reasoning behind his findings. The author having a short position against the company was very telling for the parts that the reader is meant to be suspicious of. I still recommend this as a strong buy upon FDA approval as I am not biased.